USA - NASDAQ:MOR - US6177602025 - ADR
The current stock price of MOR is 18.96 USD. In the past month the price increased by 1.94%. In the past year, price increased by 144.65%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.3 | 398.39B | ||
| AMGN | AMGEN INC | 13.37 | 157.02B | ||
| GILD | GILEAD SCIENCES INC | 15.2 | 146.02B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.74 | 107.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| ARGX | ARGENX SE - ADR | 90.34 | 51.23B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.06 | 34.49B | ||
| NTRA | NATERA INC | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.29B | ||
| BIIB | BIOGEN INC | 9.29 | 21.81B |
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
MorphoSys AG
Semmelweisstr. 7
Planegg BAYERN 82152 DE
CEO: Jean-Paul Kress
Employees: 464
Phone: 4989899270
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
The current stock price of MOR is 18.96 USD. The price increased by 2.43% in the last trading session.
MOR does not pay a dividend.
MOR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MOR.
MorphoSys AG (MOR) has a market capitalization of 2.86B USD. This makes MOR a Mid Cap stock.
MorphoSys AG (MOR) will report earnings on 2024-08-29, after the market close.
ChartMill assigns a technical rating of 9 / 10 to MOR. When comparing the yearly performance of all stocks, MOR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MOR. Both the profitability and financial health of MOR have multiple concerns.
Over the last trailing twelve months MOR reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -160.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
12 analysts have analysed MOR and the average price target is 5.06 USD. This implies a price decrease of -73.33% is expected in the next year compared to the current price of 18.96.
For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR